Drug intelligence / Profile preview

Zhima Qianzi Capsules

Development stage: Unknown
Lead developer: Zhejiang Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Zhima Qianzi Capsules is a Traditional Chinese Medicine (TCM) formulation developed by The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine. It is specifically investigated for the management of bortezomib-induced peripheral neuropathy (BIPN) in patients with multiple myeloma. The drug is typically evaluated in patients who have failed to respond to standard neuroprotective agents such as mecobalamin. As a TCM preparation, it is designed to alleviate symptoms of neurotoxicity and improve quality of life by addressing the systemic imbalances associated with chemotherapy-induced nerve damage, according to traditional Chinese medical principles.

Brand names: Zhima Qianzi Capsules
Other names: Zhima Qianzi Jiaonang

Beyond the preview

Go deeper on Zhima Qianzi Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhima Qianzi Capsules.

Explore the full profile